Moderna to apply for US emergency-use authorization of its COVID-19 vaccine on Monday
|Moderna Inc announced that it will apply for the emergency-use authorization of its COVID-19 vaccine in the US on Monday, as reported by Reuters.
Additional takeaways
"Will apply on Monday for conditional approval of its the vaccine in the EU."
"COVID-19 vaccine was 94.1% effective in analysis of phase 3 study after 196 COVID-19 cases."
"COVID-19 vaccine was 100% effective against severe COVID-19 in phase 3 trial."
"Phase 3 COVID-19 vaccine trial had 30 severe cases, all on the placebo side, including 1 death."
"US FDA Advisory Committee meeting to be scheduled for Dec. 17."
"Launch trial of COVID-19 vaccine in adolescents expected to be before the end of the year."
"No new serious safety concerns identified since Nov. 16 in phase 3 trial."
"Expecting to have 20 million doses of vaccine available in the US this year, can start shipping shortly after authorization."
"Efficacy of COVID-19 vaccine was consistent across age, race and ethnicity, and gender demographics."
Market reaction
This headline doesn't seem to be having a significant impact on market sentiment. As of writing, the S&P 500 Futures were down 0.24% on the day at 3,627.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.